首页> 外文OA文献 >Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

【2h】

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

机译：早晨给药0.4U / kg /天胰岛素冰柱300 u / ml提供较少的24小时药效动动力学和更均匀的药代动力学曲线，与1型糖尿病中的胰岛素Degludec 100u / ml相比

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
T.S. Bailey; J. Pettus; R. Roussel; W. Schmider; M. Maroccia; N. Nassr; O. Klein; G.B. Bolli; R. Dahmen;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. In response to: Heise T, N?rskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab Diabetes Obes Metab . 2017;19:1032–1039 [J] . Becker Reinhard H.A. Diabetes, obesity & metabolism . 2018,第8期

机译：响应：Heise T，N？Rskov M，Nosek L，Kaplan K，Famulla S和Haahr HL（2017）胰岛素Degludec：与类型的胰岛素龟头U300相比，药效学反应的日常日期和日期内变异性 1糖尿病。糖尿病互补糖尿病obes metab。 2017; 19：1032-1039
2. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes [J] . Heise Tim, Norskov Marianne, Nosek Leszek, Diabetes, obesity & metabolism . 2017,第7期

机译：胰岛素Degludec：与1型糖尿病患者的胰岛素龟头300 u / ml相比，药效表反应的日常日常和日期内变异性
3. Insulin glargine 300 U/mL (Gla-300) provides more stable and more evenly distributed steady-state PK/PD profiles compared with insulin degludec in type 1 diabetes [J] . Roussel R., Bailey T., Dahmen R., Fundamental & clinical pharmacology. . 2017,第Suppla1期

机译：与1型糖尿病的胰岛素Degludec相比，胰岛素冰柱300u / ml（GLA-300）提供更稳定和更均匀分布的稳态PK / PD型材
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes [O] . Tim Heise, Marianne Nørskov, Leszek Nosek, -1

机译：地格曲胰岛素：与1型糖尿病的甘精胰岛素300 / U / mL相比药效学响应的每日和当日差异较低
6. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units/mL and Insulin Degludec 100 units/mL in Type 1 Diabetes [O] . Paola Lucidi, Paola Candeloro, Patrizia Cioli, 2020

机译：临床，当量剂量胰岛素胰岛素300单位/ ml和胰岛素Degludec 100单位/ ml在1型糖尿病中的药代动力学和药效学前针比较

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes

著录项

相似文献

相关主题

期刊订阅